Statements (50)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:Company
|
gptkbp:aimsTo |
improve access to medicines
|
gptkbp:collaboratesWith |
healthcare_providers
|
gptkbp:contributedTo |
public health
|
gptkbp:distributes |
healthcare_products
|
gptkbp:employs |
pharmaceutical professionals
|
gptkbp:engagesIn |
research and development
|
gptkbp:focusesOn |
generic drugs
|
gptkbp:hasCollaborationsWith |
non-profit organizations
research institutions |
gptkbp:hasContribution |
Europe
|
gptkbp:hasEvents |
ISO certification
|
gptkbp:hasFunding |
biotechnology
|
gptkbp:hasGoals |
market expansion
|
gptkbp:hasHistoricalSignificance |
gptkb:London
|
gptkbp:hasPart |
gptkb:Cipla_UK_Limited
|
gptkbp:hasParticipatedIn |
gptkb:NHS
|
gptkbp:hasPartnershipsWith |
local distributors
healthcare_organizations |
gptkbp:hasProductLine |
respiratory therapy
|
gptkbp:hasResearchInterest |
gptkb:UK
|
https://www.w3.org/2000/01/rdf-schema#label |
Cipla's UK business
|
gptkbp:isActiveIn |
oncology
|
gptkbp:isEngagedIn |
community outreach programs
sustainability initiatives pharmaceutical education programs |
gptkbp:isFocusedOn |
therapeutic areas
patient-centric solutions |
gptkbp:isInvolvedIn |
patient advocacy
supply chain management digital health initiatives healthcare education UK_regulations |
gptkbp:isKnownFor |
affordable medicines
high-quality generics supply of essential medicines |
gptkbp:isPartOf |
global pharmaceutical market
Cipla's_corporate_social_responsibility_efforts Cipla's_global_strategy |
gptkbp:isRecognizedBy |
industry awards
|
gptkbp:isRecognizedFor |
innovation in healthcare
|
gptkbp:isSupportedBy |
government policies
|
gptkbp:offers |
prescription medications
|
gptkbp:offersServices |
chronic obstructive pulmonary disease
|
gptkbp:operatesIn |
gptkb:United_Kingdom
|
gptkbp:participatesIn |
clinical trials
|
gptkbp:partOf |
gptkb:Cipla_Limited
|
gptkbp:provides |
patient support programs
|
gptkbp:targets |
chronic diseases
|
gptkbp:wasEstablishedIn |
2000s
|